Objectives: We hypothesized that 3D time-of-flight (TOF) and true fast imaging with steady-state precession (true-FISP) fusion imaging could provide more information regarding the arterial vessel wall. The purpose of this study was to compare the accuracy of lesion detection and the diagnostic confidence of VAD between TOF images alone and fused TOF and true-FISP images.
Methods: Fifty patients were studied: 17 had VAD and 33 had vertebral artery hypoplasia. Fusion images of the vertebral artery were reconstructed using a workstation. A receiver-operating characteristic (ROC) analysis was conducted with a continuous rating scale from 1 to 100 to compare observer performance in VAD detection. Five radiologists participated in the observer performance test, and their performances with TOF images were compared with those using fused images.
Result: The observers found that the mean areas under the best-fit ROC curve for TOF images alone and fused TOF images were 0.66 ± 0.05 and 0.93 ± 0.04, which were significantly different (P < 0.01).
Conclusion: The fusion images provided more information regarding the arterial vessel wall. Fused images aided distinction between vertebral artery dissection versus vertebral artery hypoplasia.
Key Points: • New MR techniques can help to differentiate flowing blood from static blood products. • Fused TOF and true-FISP images differentiate the lumen and the arterial wall, improving diagnostic performance. • Fused images may be superior to time-of-flight MR angiography alone.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579991 | PMC |
http://dx.doi.org/10.1007/s13244-012-0204-x | DOI Listing |
Phys Med Biol
January 2025
Institute of High Energy Physics Chinese Academy of Sciences, 19B Yuquan Road, Shijingshan District, Beijing, Beijing, Beijing, 100049, CHINA.
Objective: Timing calibration is essential for positron emission tomography (PET) system as it enhances timing resolution to improve image quality. Traditionally, positron sources are employed for timing calibration. However, the photons emitted by these sources travel in opposite directions, necessitating that positrons annihilate at multiple locations to collect coincidence data across a greater number of lines of response (LORs).
View Article and Find Full Text PDFEJNMMI Phys
January 2025
Sherbrooke Molecular Imaging Center and Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 12th Avenue N, Sherbrooke, J1H 5N4, Québec, Canada.
Background: The renewed interest in BGO scintillators for TOF-PET is driven by the improved Cherenkov photon detection with new blue-sensitive SiPMs. However, the slower scintillation light from BGO causes significant time walk with leading edge discrimination (LED), which degrades the coincidence time resolution (CTR). To address this, a time walk correction (TWC) can be done by using the rise time measured with a second threshold.
View Article and Find Full Text PDFActa Neurochir (Wien)
January 2025
Department of Neurosurgery, Hebei General Hospital, 348# Heping Road, Shijiazhuang City, 050000, Hebei Province, China.
Objective: To explore the correlation between posterior fossa crowding and the occurrence of classical trigeminal neuralgia (TN).
Methods: A total of 60 patients diagnosed with classical TN and 60 age- and sex-matched healthy volunteers were included as a control group for a case-control study. All subjects underwent high-resolution 3D magnetic resonance imaging (MRI) examinations (including 3D-FIESTA and 3D-TOF MRA sequences).
J Med Chem
January 2025
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
In this study, a novel antibody-drug conjugate (ADC) consisting of Rituximab and Chlorambucil (Rituximab-CMB) was synthesized. The average number of drug molecules attached per Rituximab molecule was determined using MALDI-TOF mass spectrometry, revealing a range of 4-6 drug molecules per antibody. To further improve the therapeutic potential of the ADC, it was radiolabeled with the therapeutic radionuclide Lu via a DOTA chelator, achieving a final radiochemical purity of over 95%.
View Article and Find Full Text PDFJ Pharm Biomed Anal
January 2025
Clinical Institute of Laboratory Diagnostics, University Hospital Centre Osijek, J. Huttlera 4, Osijek 31 000, Croatia; Faculty of Medicine Osijek, JJ Strossmayer University of Osijek, J. Huttlera 4, Osijek 31 000, Croatia. Electronic address:
Ibrutinib and acalabrutinib, Bruton's tyrosine kinase inhibitors (BTKi) used for chronic lymphocytic leukemia (CLL) treatment, aim the same target but their off-target effects are different. The aim of this study was to use single-cell MALDI TOF mass spectrometry imaging to compare the CD19+ lymphocytes' mass spectra in untreated and ibrutinib- or acalabrutinib-treated subjects in order to better understand the therapeutic effect of BTKi. 180 cells from 9 male subjects divided in 3 groups (untreated, ibrutinib-treated and acalabrutinib-treated) were analyzed using MALDI-TOF mass spectrometry analyzer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!